文献速递胃肠动力与功能性疾病

针刺治疗肠易激综合征的疗效(ACTION):多中心随机对照试验

Efficacy of ACupuncTure in Irritable bOwel syNdrome (ACTION): A Multicenter Randomized Controlled Trial.
PubMed 文献 · Gastroenterology · 2025-05-27

在中国6家医院开展的 multicenter 随机对照试验中,280例腹泻型肠易激综合征患者按1:1随机接受6周15次针刺或假针刺,随访12周。第6周复合应答率针刺组57.9% vs 假针刺组41.4%(风险比1.40,P=.008)。针刺改善腹痛和大便稠度,疗效持续18周,未报告严重不良事件;作者认为针刺可能作为腹泻型肠易激综合征的替代治疗。

要点

  • 针刺组第6周复合应答率57.9%,假针刺组41.4%,风险比1.40,P=.008。
  • 组间差异自第3周起显著,除第16周外持续至研究结束。
  • 未报告严重不良事件;作者认为针刺可能作为腹泻型肠易激综合征的替代治疗。

核心结论

  • 针刺改善腹泻型肠易激综合征患者的腹痛和大便稠度,疗效持续18周。
  • 作者认为针刺可能作为腹泻型肠易激综合征的替代治疗。

研究设计与样本

  • 多中心随机对照试验,在中国6家医院开展。
  • 纳入18至75岁符合罗马IV诊断标准的腹泻型肠易激综合征患者280例,按1:1随机分配。
  • 针刺组与假针刺组(钝头针刺激非穴位)均接受6周共15次治疗,随访12周。
  • 主要结局为第6周复合应答率,定义为第6周期间平均最严重腹痛较基线改善至少30%且腹泻天数较基线减少50%或以上。

主要发现

  • 2021年5月至2022年8月共评估584例患者,其中280例被随机分配。
  • 第6周达到主要结局者针刺组71例(57.9%)vs 假针刺组47例(41.4%),风险比1.40,P=.008。
  • 组间差异自第3周起显著,除第16周外持续至研究结束。
  • 未报告严重不良事件。

临床怎么用

  • 作者认为针刺可能作为腹泻型肠易激综合征的替代治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Irritable bowel syndrome (IBS) affects 4.1% of the adult population, with many reporting ongoing symptoms despite first-line therapies. Acupuncture is widely used for IBS, but without sufficient evidence. We aimed to assess the efficacy of acupuncture in patients with diarrhea-predominant IBS (IBS-D). METHODS: This was a multicenter randomized controlled trial in 6 hospitals in China. Patients aged 18 to 75 years with IBS-D per Rome IV diagnostic criteria were randomly allocated (1:1) to receive 15 sessions of acupuncture or sham acupuncture (blunt-tipped needle at non-acupoints) over 6 weeks with a 12-week follow-up. The primary outcome was the composite response rate at week 6, defined as at least a 30% improvement in the mean worst abdominal pain and a 50% or more reduction in the number of days with diarrhea from baseline during week 6. RESULTS: Between May 2021 and August 2022, 584 patients were assessed for eligibility, of whom 280 were randomly allocated. The primary outcome was reached by 71 (57.9%) patients in the acupuncture group compared with 47 (41.4%) patients in the sham acupuncture group (risk ratio 1.40; P = .008). The between-group difference became significant from week 3 and maintained throughout the study except week 16. No severe adverse event was reported. CONCLUSIONS: Acupuncture improved abdominal pain and stool consistency in patients with IBS-D, with sustained efficacy over 18 weeks. The results of this trial suggest that acupuncture may serve as an alternative treatment for IBS-D. (ACTION Chinese Clinical Trial Registry number, ChiCTR2100044762).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Yang JW, Qi LY, Yan SY, et al. Efficacy of ACupuncTure in Irritable bOwel syNdrome (ACTION): A Multicenter Randomized Controlled Trial. Gastroenterology. 2025. PMID: 40441496. doi:10.1053/j.gastro.2025.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。